Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer

    loading  Checking for direct PDF access through Ovid

Abstract

Oral abiraterone acetate (Zytiga®), a selective cytochrome P450 17A1 enzyme inhibitor, is used in combination with prednisone or prednisolone to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. In a clinical trial in patients with CRPC, abiraterone acetate plus prednisone significantly prolonged overall survival, the time to prostate-specific antigen progression and progression-free survival compared with placebo plus prednisone.

Related Topics

    loading  Loading Related Articles